TIROSINT-SOL
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TIROSINT-SOL (TIROSINT-SOL).
Synthetic levothyroxine (T4) is deiodinated to triiodothyronine (T3), which binds to thyroid hormone receptors, activating gene transcription and increasing cellular metabolism.
| Metabolism | Hepatic metabolism via deiodination (D1, D2, D3 isoenzymes; D2 produces T3), glucuronidation (UGT1A), and sulfation; less than 20% excreted unchanged in feces and urine. |
| Excretion | Renal (biliary/fecal minimal): <20% unchanged in urine; majority metabolized then conjugated and excreted in bile/feces. |
| Half-life | Levothyroxine (T4) terminal half-life: 6–7 days in euthyroid, prolonged in hypothyroidism (9–10 days), shortened in hyperthyroidism (3–4 days). Clinical context: steady-state reached after 4–6 weeks. |
| Protein binding | >99.9% bound to thyroxine-binding globulin (TBG), transthyretin, and albumin. |
| Volume of Distribution | 0.10–0.15 L/kg; reflects distribution into lean tissues and thyroid hormone receptors. |
| Bioavailability | Oral: 40–80% (fasting, empty stomach). TIROSINT-SOL liquid formulation has higher relative bioavailability (~90%) compared to tablets. |
| Onset of Action | Oral: 3–5 days for measurable metabolic effects; full effect may take 2–3 weeks. |
| Duration of Action | Single oral dose: metabolic effects persist for 2–4 weeks; clinical duration corresponds to half-life and tissue stores. |
Initial dose 1.6 mcg/kg orally once daily; adjust by 12.5-25 mcg increments every 4-6 weeks based on TSH; typical maintenance 100-125 mcg/day.
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment required for GFR < 60 mL/min; monitor TSH closely in end-stage renal disease as levothyroxine clearance may be reduced. |
| Liver impairment | No specific Child-Pugh based adjustments; monitor TSH closely in severe hepatic impairment as metabolism may be impaired. |
| Pediatric use | Neonates: 10-15 mcg/kg/day orally once daily; Children >1 year: 4-5 mcg/kg/day; Adolescents: 2-3 mcg/kg/day; adjust based on TSH and T4. |
| Geriatric use | Start at lower dose 25-50 mcg/day orally once daily; adjust by 12.5 mcg increments every 4-6 weeks; target TSH 4-6 mIU/L due to higher risk of cardiac effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for TIROSINT-SOL (TIROSINT-SOL).
| Breastfeeding | Levothyroxine is secreted into breast milk in minimal amounts (M/P ratio approximately 2.2). Doses up to 300 mcg/day produce negligible serum levothyroxine levels in breastfed infants. No adverse effects reported. Breastfeeding is considered safe with continued maternal therapy. Monitor infant thyroid function if maternal dose is very high. |
| Teratogenic Risk | Levothyroxine (TIROSINT-SOL) is FDA Pregnancy Category A. No increased risk of fetal malformations when maternal hypothyroidism is treated. Untreated maternal hypothyroidism is associated with increased risks of miscarriage, gestational hypertension, placental abruption, and impaired fetal neurodevelopment. Adequate maternal thyroid hormone levels are critical for fetal brain development, particularly in the first trimester before fetal thyroid function begins. |
■ FDA Black Box Warning
Not for the treatment of obesity or weight loss; ineffective and dangerous at high doses.
| Serious Effects |
Uncorrected adrenal insufficiency; untreated thyrotoxicosis; hypersensitivity to any ingredient; acute myocardial infarction (relative).
| Precautions | Cardiac toxicity (arrhythmias, ischemia, palpitations) at high doses; adrenal insufficiency (must be corrected before treatment); worsening angina or congestive heart failure; need for dose adjustment in pregnancy; interactions with warfarin, antidiabetic agents, and other medications. |
Loading safety data…
| Fetal Monitoring | Monitor maternal serum TSH and free T4 every 4-6 weeks during pregnancy, and after any dose adjustment. Maintain TSH within trimester-specific reference ranges (first trimester 0.1-2.5 mIU/L, second 0.2-3.0, third 0.2-3.5). Assess maternal thyroid function postpartum if dose was increased during pregnancy. For fetus, assess growth and development via ultrasound; guideline recommends TSH screening at birth if maternal hypothyroidism is treated. |
| Fertility Effects | Untreated hypothyroidism can cause anovulatory cycles, menstrual irregularities, and infertility. Achieving euthyroid state with levothyroxine restores normal ovulatory function and improves fertility outcomes. No direct adverse effects on gametes or embryo. Continue therapy during assisted reproductive technology cycles. |